

MTN 039 - Safety and PK Study of TAF/EVG Administered Rectally
Report Generation Date: April 28, 2020
Visit Cutoff Date: March 31, 2020¹
Retention by Visit and Site

	Pittsburgh	Birmingham	All Sites
Participants Enrolled	4	4	8
Visit 3: Dose 1			
Expected ²	3	3	6
Completed ³	2 (67%)	1 (33%)	3 (50%)
Not Completed	1 (33%)	2 (67%)	3 (50%)
Missed	1 (33%)	2 (67%)	3 (50%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	1	1	2
Visit 4: 24hr Post-dose			
Expected ²	3	3	6
Completed ³	2 (67%)	1 (33%)	3 (50%)
Not Completed	1 (33%)	2 (67%)	3 (50%)
Missed	1 (33%)	2 (67%)	3 (50%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	1	1	2
Visit 5: 48hr Post-dose			
Expected ²	3	3	6
Completed ³	2 (67%)	1 (33%)	3 (50%)
Not Completed	1 (33%)	2 (67%)	3 (50%)
Missed	1 (33%)	2 (67%)	3 (50%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	1	1	2
Visit 6: 72hr Post-dose			
Expected ²	2	3	5
Completed ³	2 (100%)	1 (33%)	3 (60%)
Not Completed	0 (0%)	2 (67%)	2 (40%)
Missed	0 (0%)	2 (67%)	2 (40%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	2	1	3

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 039 - Safety and PK Study of TAF/EVG Administered Rectally
Report Generation Date: April 28, 2020
Visit Cutoff Date: March 31, 2020¹
Retention by Visit and Site

	Pittsburgh	Birmingham	All Sites
Visit 7: Dose 2			
Expected ²	1	0	1
Completed ³	1 (100%)	0 (-%)	1 (100%)
Not Completed	0 (0%)	0 (-%)	0 (0%)
Missed	0 (0%)	0 (-%)	0 (0%)
Terminated Early	0 (0%)	0 (-%)	0 (0%)
Not Expected	3	4	7
Visit 8: 24hr Post-dose			
Expected ²	1	0	1
Completed ³	1 (100%)	0 (-%)	1 (100%)
Not Completed	0 (0%)	0 (-%)	0 (0%)
Missed	0 (0%)	0 (-%)	0 (0%)
Terminated Early	0 (0%)	0 (-%)	0 (0%)
Not Expected	3	4	7
Visit 9: 48hr Post-dose			
Expected ²	1	0	1
Completed ³	1 (100%)	0 (-%)	1 (100%)
Not Completed	0 (0%)	0 (-%)	0 (0%)
Missed	0 (0%)	0 (-%)	0 (0%)
Terminated Early	0 (0%)	0 (-%)	0 (0%)
Not Expected	3	4	7
Visit 10: 72hr Post-dose			
Expected ²	1	0	1
Completed ³	1 (100%)	0 (-%)	1 (100%)
Not Completed	0 (0%)	0 (-%)	0 (0%)
Missed	0 (0%)	0 (-%)	0 (0%)
Terminated Early	0 (0%)	0 (-%)	0 (0%)
Not Expected	3	4	7

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 039 - Safety and PK Study of TAF/EVG Administered Rectally
Report Generation Date: April 28, 2020
Visit Cutoff Date: March 31, 2020¹
Retention by Visit and Site

	Pittsburgh	Birmingham	All Sites
Final Contact			
Expected ²	1	0	1
Completed ³	1 (100%)	0 (-%)	1 (100%)
Not Completed	0 (0%)	0 (-%)	0 (0%)
Missed	0 (0%)	0 (-%)	0 (0%)
Terminated Early	0 (0%)	0 (-%)	0 (0%)
Not Expected	3	4	7

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.